ADT-1004: a First-in-class, Oral Pan-Ras Inhibitor with Robust Antitumor Activity in Preclinical Models of Pancreatic Ductal Adenocarcinoma
Molecular Cancer(2025)
Key words
Pancreatic ductal adenocarcinoma,pan-RAS inhibitor,Tumor immune microenvironment,KRAS,RAS-driven malignancies
AI Read Science
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined